Prevention of breast pain and milk secretion with bromocriptine after second-trimester abortion.
Within 24 hours after abortion, 62 patients with a mean gestational age of 19 weeks, who had either induced (n = 50) or spontaneous (n = 12) abortions were randomly allocated to three groups: Group 1, bromocriptine 2.5 mg twice daily for 2 weeks; Group 2, placebo tablets 1 tablet twice daily for 2 weeks; Group 3, no treatment. Fifty-two patients completed the study (bromocriptine n = 18, placebo n = 18 and no treatment n = 16). Placebo had no apparent influence on breast symptoms. In both the placebo group and the untreated group, breast pain and milk secretion peaked on days 3 to 7, and milk secretion often continued for 3 weeks. Only 3/34 (9%) of untreated and placebo treated patients were free of breast symptoms. Compared with placebo, bromocriptine caused a significant reduction in the objective assessment score of breast tenderness (p less than 0.05) and milk secretion (p less than 0.01), in serum prolactin (PRL) (p less than 0.001) and in the subjective assessment score of breast pain (p less than 0.01) and milk secretion (p less than 0.01). Alleviation of breast pain and prevention of milk secretion appears to be indicated after second-trimester abortion, and treatment with bromocriptine is efficacious.
Nyboe Andersen
A
A
Department of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, Denmark.
Damm
P
P
Tabor
A
A
Pedersen
I M
IM
Harring
M
M
D000028:Abortion, Induced; D000328:Adult; D001940:Breast; D001971:Bromocriptine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011388:Prolactin / Q000097:blood
D001971:Bromocriptine; D011388:Prolactin